Saluda Medical Completes U.S. Launch of CAP24 Surgical Paddle Lead for Evoke Therapy

Saluda Medical (SLD.AX) said it has completed the full U.S. commercial release of its CAP24 Surgical Paddle Lead following FDA approval earlier this year, expanding access to its Evoke System for neurosurgery and orthopedic spine practices. The device, previously limited to selected centers, enables closed-loop neuromodulation by measuring each patient's neural response and adapting stimulation with every pulse. It targets the surgical paddle lead segment, which the company said accounts for approximately 30% of U.S. spinal cord stimulation implants. Saluda said Evoke Therapy has shown durable outcomes in the EVOKE study, with more than 90% of patients who responded at three months remaining responders at 36 months. The Evoke System is indicated for chronic intractable pain of the trunk and/or limbs. SLD.AX traded at AUD 0.42, up 1.19%.